Heart-failure medicines have different jobs
Heart-failure medicines are not interchangeable tablets for “making the heart stronger”. A loop diuretic may relieve congestion, while renin-angiotensin medicines, selected beta blockers, mineralocorticoid-receptor antagonists and SGLT2 inhibitors address different disease pathways and outcomes. The combination depends on heart-failure type, symptoms, kidney function, potassium, blood pressure, rhythm, frailty and the person’s response.
Key takeaways
- Symptom relief and longer-term protection are different jobs: feeling less swollen after a diuretic does not show whether the rest of the regimen is unnecessary.
- Treatment differs between reduced, mildly reduced and preserved ejection fraction, and evidence applies to particular medicine classes, ingredients and formulations.
- Kidney function, potassium, blood pressure, pulse, fluid status, diabetes and infection risk shape monitoring; changes should follow the heart-failure plan, not an online class chart.
Why does the type of heart failure change the medicine plan?
Heart failure can occur when the left ventricle contracts weakly, when it is stiff and fills poorly, or with features between those patterns. Ejection fraction helps classify reduced, mildly reduced and preserved forms, but diagnosis also depends on symptoms, examination and evidence of abnormal heart structure or function.
Current guidelines do not assign the same medicine combination to every category. NICE’s current recommendations identify four foundational classes for heart failure with reduced ejection fraction: an ACE inhibitor, an evidence-based beta blocker, a mineralocorticoid-receptor antagonist and an SGLT2 inhibitor, with alternatives or an ARNI considered in defined circumstances. Its recommendations differ for mildly reduced and preserved ejection fraction.
That is why a normal-looking ejection-fraction number does not exclude heart failure, and why a relative’s medicine list is not a template.
Which medicines mainly relieve fluid symptoms?
Loop diuretics such as furosemide increase salt and water removal and can reduce ankle swelling or breathlessness caused by congestion. The visible response can be rapid compared with the less noticeable effect of other classes.
Diuresis is not a universal measure of protection, however. Too little may leave congestion; too much may contribute to dehydration, low blood pressure, kidney dysfunction or electrolyte disturbance. Daily weight and symptom instructions should be individual. Singapore HealthHub’s heart-failure medicine guidance advises following the clinician-provided furosemide plan rather than making an unplanned change.
| Medicine role | Examples in the tenant | Main comparison question |
|---|---|---|
| Relieve congestion | Furosemide | Are fluid symptoms improving without dehydration, kidney or electrolyte problems? |
| Modify renin-angiotensin pathways | Ramipril and related ACE inhibitor/ARB/ARNI options | What do kidney function, potassium, blood pressure, cough or angioedema history allow? |
| Reduce harmful sympathetic drive | Selected agents such as bisoprolol | Is this an evidence-based ingredient/formulation for the heart-failure type, introduced and monitored when clinically stable? |
| Block mineralocorticoid effects | Spironolactone | Are potassium and kidney function suitable and monitored? |
| SGLT2 pathway | Dapagliflozin | What do kidney function, fluid status, infection risk, fasting/acute illness and diabetes status change? |
Why are selected beta blockers used when they slow the heart?
In stable chronic heart failure with an appropriate indication, selected beta blockers reduce harmful long-term sympathetic stimulation and are part of evidence-based treatment. This does not mean every beta blocker is suitable or that a person with acutely worsening congestion should change one without specialist direction.
Bisoprolol, carvedilol and metoprolol succinate are among the agents with established reduced-ejection-fraction evidence in major guidance. Pulse, blood pressure, conduction, fatigue, wheeze and signs of worsening congestion affect introduction and adjustment. The beta-blocker comparison explains why class membership alone is insufficient.
What do kidney function and potassium connect?
ACE inhibitors, ARBs, ARNIs and MRAs all interact with kidney perfusion or potassium handling. NICE recommends checking renal function and electrolytes before these classes and monitoring after introduction and dose changes according to the clinical plan. A small change does not automatically mean treatment has failed, and a large or symptomatic change cannot be safely interpreted without the results, timing, fluid status and other medicines.
NSAIDs, dehydration, potassium supplements, salt substitutes and interacting medicines can alter this balance. Spironolactone also has endocrine adverse effects in some people. A medicine review should include non-prescription painkillers, supplements and traditional medicines rather than only the cardiology list.
Why can an SGLT2 inhibitor appear on a heart-failure list without diabetes?
SGLT2 inhibitors were first used for diabetes, but current heart-failure guidelines include selected agents for heart failure independent of a simple “has diabetes/does not have diabetes” split. That does not make them ordinary diuretics or interchangeable with glucose-lowering medicines.
Monitoring and sick-day questions include kidney function, volume depletion, genital or urinary symptoms and the rare risk of ketoacidosis, which can occur without very high glucose. Fasting, acute illness, surgery and reduced food or fluid intake need clinician-provided instructions. Do not stop or restart from a generic online rule.
What changes the answer?
- Ejection fraction and cause. Reduced, mildly reduced and preserved forms have different evidence; valve disease, rhythm problems and coronary disease may require additional treatment.
- Current fluid status. Congestion, dehydration and stable weight do not call for the same diuretic response.
- Kidney function and potassium. These influence several foundational classes at the same time.
- Blood pressure, pulse and rhythm. Low pressure, bradycardia or conduction disease can limit or change sequencing.
- Frailty and other conditions. Diabetes, COPD/asthma, gout, anaemia, infection and cognitive or mobility issues affect monitoring and adherence.
- Recent hospital treatment. Discharge changes need reconciliation so old packets do not remain in use beside the new regimen.
Which symptoms need urgent assessment?
Contact the heart-failure service promptly for a rapid increase in swelling or weight according to the personal plan, worsening breathlessness with usual activity or lying flat, reduced urine, new confusion, persistent dizziness or a clear decline in function. These can reflect congestion, low output, infection, kidney problems or medicine effects and cannot be separated reliably at home.
Call 995 or attend emergency care for sudden or severe breathlessness, new chest discomfort, fainting, severe giddiness, blue or grey colour, collapse or rapidly worsening symptoms. Do not wait to see whether an extra diuretic helps unless that exact step is already written into the clinician-provided plan.
Bring all packets, the most recent discharge list, weight/symptom record and blood-test results to review. The heart-failure condition page explains the diagnosis; this article’s purpose is to make the different medicine jobs visible before a cardiology or pharmacy discussion.
Sources
- NICE: Chronic heart failure in adults—diagnosis and management.
- Singapore HealthHub: Heart Failure—Medication.
- SingHealth: Heart failure—symptoms and treatments.
- Singapore Agency for Care Effectiveness: Sacubitril/valsartan for chronic heart failure with reduced ejection fraction.
- American Heart Association: Medications used to treat heart failure.
